A clinical trial shows that a combination of injectable naltrexone and extended-release oral bupropion reduces methamphetamine use for up to 12 weeks. The study found a significant increase in methamphetamine-negative urine tests among participants receiving the two-drug therapy.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A new study combines bisphosphonates, commonly used for osteoporosis, with azole antifungals to treat fungal infections. The combination effectively targets dermatophytes and prevents resistance development.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
Researchers at Dana-Farber Cancer Institute have reported encouraging results from three separate studies on treatments for central nervous system lymphoma, breast cancer, and glioblastoma. CAR T-cell therapy showed a 94% overall response rate in patients with CNS lymphoma, while an antibody-drug conjugate plus checkpoint inhibitor imp...
Researchers tested seven antibiotics in combination with various natural compounds, finding synergistic effects against multidrug-resistant bacteria. The study suggests combining antibiotics with plant extracts or phytochemicals could be a promising strategy to combat antimicrobial resistance.
A study by UCLA Health Jonsson Comprehensive Cancer Center researchers found that combining experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer. The median progression-free survival was 6.2 months compared to 2.1 months f...
Certain combinations of medication or psychotherapy with transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) are supported by clinical studies for major depressive disorder (MDD) treatment. Researchers recommend more sophisticated trial designs to move the field forward.
A review of clinical studies suggests that combining TMS or tDCS with certain types of psychotherapy or medication can lead to greater symptom reduction in patients with major depressive disorder. However, the research has limitations and more sophisticated trial designs are needed to move the field forward.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have found a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas. Adding an immune-boosting agent, poly-ICLC, to a personalized dendritic cell vaccine improves the immune response and activity of T cells in patients.
A study by Duke University researchers found that combining a low-carb, high-fat keto diet with fluconazole significantly improved treatment outcomes against fungal meningitis. The keto diet increased the effectiveness of fluconazole by reducing fungal levels by up to ten thousandfold.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
The FDA has approved the use of N-803, an immunotherapy drug, in combination with BCG for treating patients with non-muscle invasive bladder cancer who did not respond to conventional treatment. The approval is based on a trial led by UCLA's Dr. Karim Chamie, which showed improved outcomes and longer overall survival rates.
A study published in The Lancet Gastroenterology & Hepatology found that dietary adjustments, such as a low FODMAP diet and low-carbohydrate diets, resulted in significantly reduced IBS symptoms for over seven out of ten patients. In contrast, medication-based treatment showed fewer symptom improvements.
A new American Heart Association Scientific Statement highlights the importance of patient-centered care in cardiovascular health, combining expert knowledge with consideration of patients' beliefs, preferences, and values. The statement provides practical guidance on incorporating person-centered care into routine clinical practice.
Researchers from MD Anderson Cancer Center present early-phase clinical data demonstrating the efficacy of a new combination therapy, an antibody-drug conjugate, and molecularly selected patients in treating lymphoma and gastric cancers. The studies show promising initial results with improved response rates and overall survival.
A comprehensive review examines the impact of osteoporosis on fracture healing and the effects of osteoporosis medications. The study concludes that there is no deleterious effect of osteoporosis medications on fracture healing, and prompt treatment can reduce the risk of secondary fractures.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
A phase 2 study by Dana-Farber Cancer Institute investigators found notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer, including six out of 16 patients experiencing tumor reduction. The combination of mirvetuximab soravtansine and pembrolizumab met its primary endpoint and showed promise for ...
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers have found that combining DNMT and EZH2 inhibitors activates viral mimicry in cancer cells, making them more susceptible to attack by the immune system. The combination therapy has shown potential in treating colorectal cancers and other solid tumors, with an upcoming Phase I clinical trial planned.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
A new nanofluidic implant has been shown to deliver an HIV drug with increased potency compared to existing oral medications, providing a potential breakthrough in addressing treatment nonadherence. The device is intended for long-term controlled release and avoids repeated systemic treatment, which can lead to adverse side effects.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
A comparative study of four major type 2 diabetes medications reveals differences in medication acceptance, quality of life, insulin secretion, and mortality. The GRADE Study found that younger age and higher blood sugar levels at baseline were associated with poor blood sugar control over time.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Research highlights treating anxiety and depression in people with heart disease can significantly reduce emergency room visits, hospitalizations, and even death. The study found that talk therapy and antidepressant medications improved heart outcomes among those with blocked arteries or heart failure.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Recent medications for Type 2 diabetes and weight loss have positive effects on cardiovascular and kidney health but are not always prescribed or accessible to those who need them. The studies highlight the need to address barriers to access and equity, particularly among Black adults with severe obesity.
A new study found that peer-coaching is effective in controlling high blood pressure, particularly among younger Black patients. Participants under 60 who received peer coaching experienced a medically significant reduction in systolic blood pressure compared to those receiving enhanced usual care. The study also showed promise for pra...
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers investigated the impact of senolytic treatments on DNA methylation clocks and epigenetic age. Results showed significant increases in epigenetic age acceleration with Dasatinib and Quercetin treatment, but not with Fisetin addition.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
A new study aims to enhance and prolong vaccine effectiveness by delivering adjuvants to white blood cells using lipid nanoparticles. The research, led by WVU professor Sharan Bobbala, has the potential to provide broader protection against evolving viruses and multiple diseases.
Researchers at Baylor College of Medicine have developed a novel combination therapy that produced encouraging results in animal models. The therapy, which includes an inhibitor of the enzyme histone deacetylase (HDAC), showed significant tumor shrinkage and reduced alpha fetoprotein levels after just one week of treatment.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
A new clinical trial demonstrates a small reduction in the latent reservoir of HIV-infected cells using a combination of vorinostat and immunotherapy. While the results are promising, further research is needed to create more effective approaches to flush out the virus and attack it when it emerges from latency.
Researchers have developed a new approach to treating cutaneous neurofibromas, a common skin tumor associated with neurofibromatosis type 1. By targeting the cAMP and Ras/MAPK pathways, this combination therapy may provide an enduring halt in the expansion of these tumors.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
The University of Texas at Arlington is advancing its understanding of deadly disease tuberculosis (TB) with a new research project led by associate professor Kayunta Johnson-Winters. The project aims to understand why certain types of Mycobacterium tuberculosis bacteria do not respond to treatments.
A preliminary study found that most stroke survivors can safely take two common types of antidepressants without increasing the risk of hemorrhagic stroke. However, patients on dual anti-platelet therapy may be at increased risk of bleeding.
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.
Researchers found that hepatitis E virus (HEV) mutations made treatment with individual drugs less effective, highlighting the need for combination therapies. The study's findings also provide insights into the evolutionary dynamics of HEV, paving the way for next-generation antiviral treatments.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
A new international trial investigated the safety and efficacy of sabatolimab combined with hypomethylating agents in patients with myelodysplastic neoplasms. The study found manageable side effects, but no significant improvement in response rates or progression-free survival.
A study led by Amsterdam UMC found that a tailored computerised decision support system reduced high-risk drug combinations and improved patient safety. The system only showed alerts for high-risk or needing extra monitoring, resulting in 12% fewer high-risk drug combinations and shorter ICU stays.
A recent trial assessed a novel combination of local vibration and extracorporeal shock wave therapy for the effective treatment of plantar fasciitis, with results showing significant reductions in plantar fascia thickness and heel pain. The study highlights a promising therapeutic intervention to treat this common musculoskeletal cond...
Researchers identified gartisertib as a potent ATR inhibitor that enhances cell death in patient-derived glioblastoma cell lines. The study also showed synergy between gartisertib and TMZ+RT treatment, with higher sensitivity to gartisertib observed in MGMT promoter unmethylated cells.
Researchers at Kennedy Krieger and Boston Children's Hospital have discovered a new way to decrease early seizure likelihood among infants with Sturge-Weber Syndrome. Presymptomatic treatment involving anti-seizure medication and low-dose aspirin improves neurologic outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
A study by Virginia Tech researchers found that medications used to treat Type 2 diabetes, such as Ozempic and Mounjaro, can decrease cravings for alcohol and lead to reduced consumption in individuals with obesity. The findings add to a growing literature on the potential of GLP-1 agonists to curb dangerous drinking habits.